Lilly joins CGRP race to cure migraine
FDA to make decision on Amgen drug tomorrow
Lilly adds pancreatic cancer drug to pipeline
Lilly and Alder take on the might of Novartis and Amgen
New phase 3b trial results show Lilly’s Trulicity combined with an SGLT2 inhibitor failed to show any benefits above and beyond Trulicity’s blood glucose lowering.